Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

Author(s):
Cutsem, E. van; Dicato, M.; Arber, N.; Berlin, J.; Cervantes, A.; Ciardiello, F.; Gramont, A. de; Diaz-Rubio, E.; Ducreux, M.; Geva, R.; Glimelius, B.; Jones, R.G.; Grothey, A.; Gruenberger, T.; Haller, D.; Haustermans, K.; Labianca, R.; Lenz, H.J.; Minsky, B.; Nordlinger, B.; Ohtsu, A.; Pavlidis, N.; Rougier, P.; Schmiegel, W.; Velde, C. van de; Schmoll, H.J.; Sobrero, A.; Tabernero, J.
Published
2010
Publication type
Article / Letter to editor
phase-iii trial fluorouracil-based chemotherapy randomized controlled-trial advanced pancreatic-cancer cetuximab plus irinotecan microsatellite instability thymidylate synthase carcinoembryonic antigen combination chemotherapy 1st-line treatment
Date issued
2010-12-31
Language
English
Is part of
Annals of Oncology (2010), Vol. 21, p. 1-10
hdl
1887/109642